Genedrive PLC Result of AGM (2342Y)
29 December 2023 - 10:44PM
UK Regulatory
TIDMGDR
RNS Number : 2342Y
Genedrive PLC
29 December 2023
genedrive plc
("genedrive" or the "Company")
Result of AGM
genedrive plc (AIM: GDR), the point of care pharmacogenetic
testing company, announces that at the Annual General Meeting, held
today, all resolutions proposed were duly passed.
For information, details of the proxy voting are shown
below:
Resolution Votes For Votes For Votes Against Votes Against Vote Withheld
(as % of votes (as % of votes
cast) cast)
1 9,120,276 98.8% 113,243 1.2% 199,069
---------- ---------------- -------------- ---------------- --------------
2 8,958,874 97.0% 274,645 3.0% 199,069
---------- ---------------- -------------- ---------------- --------------
3 8,949,212 97.3% 243,769 2.7% 239,607
---------- ---------------- -------------- ---------------- --------------
4 8,958,212 97.4% 234,769 2.6% 239,607
---------- ---------------- -------------- ---------------- --------------
5 7,803,515 97.1% 234,769 2.9% 1,394,304
---------- ---------------- -------------- ---------------- --------------
6 9,075,202 98.4% 143,117 1.6% 214,269
---------- ---------------- -------------- ---------------- --------------
7 8,983,550 97.5% 234,769 2.5% 214,269
---------- ---------------- -------------- ---------------- --------------
8 9,061,602 98.3% 156,717 1.7% 214,269
---------- ---------------- -------------- ---------------- --------------
9 9,085,116 98.6% 126,403 1.4% 221,069
---------- ---------------- -------------- ---------------- --------------
10 8,962,881 96.1% 364,153 3.9% 105,554
---------- ---------------- -------------- ---------------- --------------
11 7,805,054 83.7% 1,519,780 16.3% 107,754
---------- ---------------- -------------- ---------------- --------------
12 8,968,751 96.2% 355,723 3.8% 108,114
---------- ---------------- -------------- ---------------- --------------
13 8,962,881 96.1% 364,153 3.9% 105,554
---------- ---------------- -------------- ---------------- --------------
14 8,960,351 96.1% 364,483 3.9% 107,754
---------- ---------------- -------------- ---------------- --------------
The full text of each of the resolutions is set out in the
notice of Annual General Meeting, copies of which are available on
the Company's website ( www.genedriveplc.com ).
For further details please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com ) genedrive
plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key
genetic information that will help them make the right choices over
the right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront of work on Point
of Care pharmacogenetics. Pharmacogenetics looks at how your
genetics impacts a medicines ability to work for you. Therefore, by
using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the
Genedrive(R) MT-RNR1 ID Kit, which is a single-use disposable
cartridge which circumvents the requirement for cold chain
logistics by providing temperature stable reagent test kits for use
on their proprietary test platform. This test allows clinicians to
make a decision on antibiotic use within 26 minutes, ensuring vital
care is delivered with no negative impact on the patient
pathway.
The Company has a clear commercial strategy focused on
accelerating growth through maximising in-market sales, geographic
and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBBBDDXSDDGXC
(END) Dow Jones Newswires
December 29, 2023 06:44 ET (11:44 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024
